INCY
Price
$67.51
Change
+$0.09 (+0.13%)
Updated
Jun 5, 04:41 PM (EDT)
Capitalization
13.05B
61 days until earnings call
REGN
Price
$483.63
Change
-$1.30 (-0.27%)
Updated
Jun 5, 04:38 PM (EDT)
Capitalization
52.36B
56 days until earnings call
Interact to see
Advertisement

INCY vs REGN

Header iconINCY vs REGN Comparison
Open Charts INCY vs REGNBanner chart's image
Incyte
Price$67.51
Change+$0.09 (+0.13%)
Volume$2.31K
Capitalization13.05B
Regeneron Pharmaceuticals
Price$483.63
Change-$1.30 (-0.27%)
Volume$300
Capitalization52.36B
INCY vs REGN Comparison Chart
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. REGN commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Buy and REGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (INCY: $67.42 vs. REGN: $484.93)
Brand notoriety: INCY and REGN are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 75% vs. REGN: 137%
Market capitalization -- INCY: $13.05B vs. REGN: $52.36B
INCY [@Biotechnology] is valued at $13.05B. REGN’s [@Biotechnology] market capitalization is $52.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than INCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • INCY’s TA Score: 5 bullish, 4 bearish.
  • REGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INCY is a better buy in the short-term than REGN.

Price Growth

INCY (@Biotechnology) experienced а +3.83% price change this week, while REGN (@Biotechnology) price change was -19.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.10%. For the same industry, the average monthly price growth was +9.95%, and the average quarterly price growth was -2.04%.

Reported Earning Dates

INCY is expected to report earnings on Aug 05, 2025.

REGN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($52.4B) has a higher market cap than INCY($13.1B). INCY has higher P/E ratio than REGN: INCY (337.10) vs REGN (12.33). INCY YTD gains are higher at: -2.389 vs. REGN (-31.735). REGN has higher annual earnings (EBITDA): 5.53B vs. INCY (407M). INCY has less debt than REGN: INCY (43.1M) vs REGN (2.71B). REGN has higher revenues than INCY: REGN (14.1B) vs INCY (4.41B).
INCYREGNINCY / REGN
Capitalization13.1B52.4B25%
EBITDA407M5.53B7%
Gain YTD-2.389-31.7358%
P/E Ratio337.1012.332,735%
Revenue4.41B14.1B31%
Total Cash2.41BN/A-
Total Debt43.1M2.71B2%
FUNDAMENTALS RATINGS
INCY vs REGN: Fundamental Ratings
INCY
REGN
OUTLOOK RATING
1..100
733
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8953
PRICE GROWTH RATING
1..100
5265
P/E GROWTH RATING
1..100
197
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for INCY (93). This means that REGN’s stock grew significantly faster than INCY’s over the last 12 months.

REGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INCY (100). This means that REGN’s stock grew similarly to INCY’s over the last 12 months.

REGN's SMR Rating (53) in the Biotechnology industry is somewhat better than the same rating for INCY (89). This means that REGN’s stock grew somewhat faster than INCY’s over the last 12 months.

INCY's Price Growth Rating (52) in the Biotechnology industry is in the same range as REGN (65). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.

INCY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for REGN (97). This means that INCY’s stock grew significantly faster than REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYREGN
RSI
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 2 days ago
53%
Bearish Trend 2 days ago
56%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
66%
Advances
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 17 days ago
61%
Declines
ODDS (%)
Bearish Trend 14 days ago
63%
Bearish Trend 2 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
60%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
METC9.930.49
+5.19%
Ramaco Resources
OGI1.340.01
+0.75%
Organigram Global Inc
JOE45.050.24
+0.54%
St Joe Company
OMC71.21-0.25
-0.35%
Omnicom Group
ALLR0.87-0.01
-1.02%
Allarity Therapeutics Inc

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with CRNX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-0.60%
CRNX - REGN
43%
Loosely correlated
+0.78%
ROIV - REGN
43%
Loosely correlated
-0.31%
IDYA - REGN
43%
Loosely correlated
-2.50%
COGT - REGN
40%
Loosely correlated
-2.59%
NTLA - REGN
40%
Loosely correlated
-0.26%
More